A novel fully human monoclonal antibody that neutralizes multiple human IFN-α subtypes effectively: a candidate therapy for SLE

Shuang Wang,Peng Du

doi:10.1186/2051-1426-3-s2-p240

Abstract

Meeting abstracts Systemic lupus erythematosus is a chronic, heterogeneous autoimmune disease, and there is no specific drug for its effective treatment, which may be because of its complexity on pathogenic mechanism. A multitude of studies of SLE in the last decade have accentuated a central role

Highlights

Systemic lupus erythematosus is a chronic, heterogeneous autoimmune disease, and there is no specific drug for its effective treatment, which may be because of its complexity on pathogenic mechanism
The Clinical Trials have proved the effectiveness of antibodies targeting multiple human IFN-a subtypes, especially the sifalimumab of AstraZeneca (IIb)
A novel fully human antibody that neutralizes multiple human IFN-a subtypes effectively was screened from fully synthetic human antibody library by Institute of Biotechnology, Academy of Military Medical Sciences

Summary

Introduction

Systemic lupus erythematosus is a chronic, heterogeneous autoimmune disease, and there is no specific drug for its effective treatment, which may be because of its complexity on pathogenic mechanism. A novel fully human monoclonal antibody that neutralizes multiple human IFN-a subtypes effectively: a candidate therapy for SLE

Results

Conclusion